{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "65",
  "slug": "trial-readouts",
  "edition": "2026-10-15T12",
  "url": "https://hangingcontext.com/stories/2026-10-15/trial-readouts/",
  "newsroom": "health-biotech",
  "beat": null,
  "newsroom_title": "Health & Biotech",
  "audience": "professional",
  "angle": "ClinicalTrials.gov logged six completed trials with results this week — read the postings, not the press releases.",
  "headline": "Six trials posted results this week, from PTSD to liver cancer",
  "dek": "Brigimadlin for solid tumors, ketamine for PTSD, a liver-cancer triple combo, bupivacaine for surgical pain, glucagon in metabolic disease, and revefenacin in COPD all reached completed-with-results.",
  "published_at": "2026-10-15T12:44:12Z",
  "labels": {
    "trust": "reported",
    "trust_text": "Reported · 6 sources",
    "newsroom": "Health & Biotech"
  },
  "source_count": 6,
  "publishers": [
    "nih-clinical-trials-phase-2-completed-results",
    "nih-clinical-trials-phase-4-completed-results"
  ],
  "key_facts": [
    {
      "text": "Brightline-2 (NCT05512377), a Phase 2 trial of brigimadlin (BI 907828) sponsored by Boehringer Ingelheim, is completed. It enrolled patients with pancreatic neoplasms, solid tumors, biliary tract cancer, lung neoplasms, and bladder cancer.",
      "self_reported": false,
      "cites": [
        {
          "manifest_id": "1791981868392502404",
          "claim_ids": [
            "1791982257169273230",
            "1791982257191450093",
            "1791982257200546519",
            "1791982257205261235",
            "1791982257207510954"
          ]
        }
      ]
    },
    {
      "text": "The Minneapolis Veterans Affairs Medical Center completed a Phase 2 trial (NCT03960658) testing ketamine-enhanced prolonged exposure for PTSD. The study is officially recorded as completed with results.",
      "self_reported": false,
      "cites": [
        {
          "manifest_id": "1791981868392680614",
          "claim_ids": [
            "1791982254388688908",
            "1791982254391283396",
            "1791982254393612536"
          ]
        }
      ]
    },
    {
      "text": "A Bristol-Myers Squibb Phase 2 trial (NCT05337137) of nivolumab, relatlimab, and bevacizumab in advanced hepatocellular carcinoma is completed with results posted. The study tested the triple combination against a placebo.",
      "self_reported": false,
      "cites": [
        {
          "manifest_id": "1791981868392357036",
          "claim_ids": [
            "1791982254281881891",
            "1791982254283959467",
            "1791982254284483978",
            "1791982254286778393"
          ]
        }
      ]
    },
    {
      "text": "A Phase 4 trial (NCT04362566) of bupivacaine for postoperative pain in Mohs surgery, run against a placebo saline intervention, is completed with results posted. Sponsors were the University of Missouri-Columbia, the University of Pennsylvania, and Columbia University.",
      "self_reported": false,
      "cites": [
        {
          "manifest_id": "1791981869274942141",
          "claim_ids": [
            "1791982256724128459",
            "1791982256727427205",
            "1791982256739288980",
            "1791982256735570508"
          ]
        }
      ]
    },
    {
      "text": "A Phase 2 trial (NCT05500586) on the effects of glucagon on hepatic metabolism in patients with obesity, type 2 diabetes, and NAFLD is completed with results. It was sponsored by Adrian Vella and the National Institute of Diabetes and Digestive and Kidney Diseases.",
      "self_reported": false,
      "cites": [
        {
          "manifest_id": "1791981868392495054",
          "claim_ids": [
            "1791982257505771993",
            "1791982257507534884",
            "1791982257509348949"
          ]
        }
      ]
    },
    {
      "text": "A Phase 2 trial (NCT04315558) of revefenacin inhalation solution (Yupelri) in COPD patients with acute respiratory failure is completed with results posted. Sponsors included UCLA, Theravance Biopharma, and Mylan Pharmaceuticals.",
      "self_reported": false,
      "cites": [
        {
          "manifest_id": "1791981868392398415",
          "claim_ids": [
            "1791982258039957693",
            "1791982258049654765",
            "1791982258059071515",
            "1791982258062433608",
            "1791982258057739990"
          ]
        }
      ]
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "The oncology trio",
      "paragraphs": [
        {
          "markdown": "Two of the six completions sit in oncology's hardest corners. The Brightline-2 study (NCT05512377) is a Phase 2 trial of brigimadlin (BI 907828) that has reached completed status. Boehringer Ingelheim's trial enrolled a deliberately broad solid-tumor population — pancreatic neoplasms, biliary tract cancer, lung neoplasms, bladder cancer, and solid tumors generally — which is the profile of a drug being tested for a tissue-agnostic signal rather than a single-indication bet.",
          "cites": [
            {
              "manifest_id": "1791981868392502404",
              "claim_ids": [
                "1791982257169273230",
                "1791982257191450093",
                "1791982257200546519",
                "1791982257205261235",
                "1791982257207510954"
              ]
            }
          ]
        },
        {
          "markdown": "The liver-cancer entry is a combination play. Bristol-Myers Squibb's Phase 2 trial (NCT05337137) tested nivolumab plus relatlimab plus bevacizumab in advanced hepatocellular carcinoma against a placebo, and the registry now shows it completed with results posted. Three-drug regimens in HCC are where the field has been pushing since single-agent immunotherapy plateaued, so the posted results — not the completion — are what matter here.",
          "cites": [
            {
              "manifest_id": "1791981868392357036",
              "claim_ids": [
                "1791982254281881891",
                "1791982254283959467",
                "1791982254284483978",
                "1791982254286778393"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "Brain, lungs, metabolism",
      "paragraphs": [
        {
          "markdown": "The most watched completion may be the smallest trial. The Minneapolis Veterans Affairs Medical Center completed a Phase 2 trial (NCT03960658) testing ketamine-enhanced prolonged exposure for PTSD, and the study is officially recorded as completed with results. The concept is pharmacological enhancement of psychotherapy — ketamine administered alongside prolonged exposure — and the VA setting means the population is veterans, the group with the most to gain if the combination works.",
          "cites": [
            {
              "manifest_id": "1791981868392680614",
              "claim_ids": [
                "1791982254388688908",
                "1791982254391283396",
                "1791982254393612536"
              ]
            }
          ]
        },
        {
          "markdown": "Two more completions fill out the week. A Phase 2 trial (NCT04315558) of revefenacin inhalation solution (Yupelri) in COPD patients with acute respiratory failure — sponsored by UCLA, Theravance Biopharma, and Mylan Pharmaceuticals — is completed with results posted. And a Phase 2 trial (NCT05500586) on the effects of glucagon on hepatic metabolism in patients with obesity, type 2 diabetes, and NAFLD, sponsored by Adrian Vella and the National Institute of Diabetes and Digestive and Kidney Diseases, is completed with results.",
          "cites": [
            {
              "manifest_id": "1791981868392398415",
              "claim_ids": [
                "1791982258039957693",
                "1791982258049654765",
                "1791982258059071515",
                "1791982258062433608",
                "1791982258057739990"
              ]
            },
            {
              "manifest_id": "1791981868392495054",
              "claim_ids": [
                "1791982257505771993",
                "1791982257507534884",
                "1791982257509348949"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "Pain, post-surgery",
      "paragraphs": [
        {
          "markdown": "The week's only Phase 4 completion is refreshingly concrete. Trial NCT04362566 tested bupivacaine for postoperative pain in Mohs surgery — the skin-cancer procedure done under local anesthesia — against a placebo saline intervention. The trial, sponsored by the University of Missouri-Columbia, the University of Pennsylvania, and Columbia University, is completed with results posted. Post-op pain in dermatologic surgery is an everyday clinical question, and a completed placebo-controlled answer is genuinely useful.",
          "cites": [
            {
              "manifest_id": "1791981869274942141",
              "claim_ids": [
                "1791982256724128459",
                "1791982256727427205",
                "1791982256739288980",
                "1791982256735570508"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "What it adds up to",
      "paragraphs": [
        {
          "markdown": "This is reasoning: a registry week like this is a reminder that completion is not a result. Six trials finished, six result sets posted, zero outcomes summarized in the registry metadata itself. The discipline for pipeline watchers is to read the postings — the primary endpoints, the adverse events tables, the actual numbers — before updating any model of these programs. The trials worth opening first are the ones where the question is sharpest: ketamine plus exposure therapy in veterans with PTSD, and the triple combination in advanced liver cancer.",
          "cites": [
            {
              "manifest_id": "1791981868392502404",
              "claim_ids": [
                "1791982257191450093"
              ]
            },
            {
              "manifest_id": "1791981868392680614",
              "claim_ids": [
                "1791982254393612536"
              ]
            },
            {
              "manifest_id": "1791981868392357036",
              "claim_ids": [
                "1791982254284483978"
              ]
            }
          ]
        },
        {
          "markdown": "This is reasoning: note the concentration. Three of the six are oncology, and two of those sit in gastrointestinal cancers — pancreatic, biliary, liver — where the unmet need is highest and the trial bar is brutal. The other three are spread across psychiatry, pulmonology, metabolic disease, and surgical pain: the registry's long tail doing its quiet work.",
          "cites": [
            {
              "manifest_id": "1791981868392502404",
              "claim_ids": [
                "1791982257207510954"
              ]
            },
            {
              "manifest_id": "1791981868392357036",
              "claim_ids": [
                "1791982254281881891"
              ]
            }
          ]
        }
      ]
    }
  ],
  "unresolved": [
    "The registry metadata confirms completion and posted results but not the outcomes — efficacy and safety conclusions require reading the posted result sets.",
    "Whether the revefenacin and glucagon postings change practice depends on effect sizes not visible in the registry summaries.",
    "Publication timelines for peer-reviewed papers on these six trials are not stated in the registry entries."
  ],
  "decision_card": {
    "useful_for": [
      "Pipeline watchers tracking which programs actually finished",
      "Clinicians flagging new data in their indications"
    ],
    "not_for": [
      "Treatment decisions — these are registry postings, not medical guidance",
      "Assuming efficacy from completion status alone"
    ],
    "compare_against": [
      "ClinicalTrials.gov postings for the individual NCT numbers",
      "prior readouts in the same indications"
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-10-15T12"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1791981868392502404",
    "1791981868392680614",
    "1791981868392357036",
    "1791981869274942141",
    "1791981868392495054",
    "1791981868392398415"
  ],
  "manifests": [
    {
      "manifest_id": "1791981868392502404",
      "title": "Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder",
      "source_name": "nih-clinical-trials-phase-2-completed-results",
      "source_url": "https://clinicaltrials.gov/study/NCT05512377?aggFilters=phase%3A2%2Cresults%3Awith%2Cstatus%3Acom",
      "published_date": "2026-10-14"
    },
    {
      "manifest_id": "1791981868392680614",
      "title": "Ketamine and Prolonged Exposure in PTSD",
      "source_name": "nih-clinical-trials-phase-2-completed-results",
      "source_url": "https://clinicaltrials.gov/study/NCT03960658?aggFilters=phase%3A2%2Cresults%3Awith%2Cstatus%3Acom",
      "published_date": "2026-10-14"
    },
    {
      "manifest_id": "1791981868392357036",
      "title": "A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer",
      "source_name": "nih-clinical-trials-phase-2-completed-results",
      "source_url": "https://clinicaltrials.gov/study/NCT05337137?aggFilters=phase%3A2%2Cresults%3Awith%2Cstatus%3Acom",
      "published_date": "2026-10-14"
    },
    {
      "manifest_id": "1791981869274942141",
      "title": "Bupivacaine for Post-operative Pain in Mohs",
      "source_name": "nih-clinical-trials-phase-4-completed-results",
      "source_url": "https://clinicaltrials.gov/study/NCT04362566?aggFilters=phase%3A4%2Cresults%3Awith%2Cstatus%3Acom",
      "published_date": "2026-10-14"
    },
    {
      "manifest_id": "1791981868392495054",
      "title": "The Effects of Glucagon on Hepatic Metabolism",
      "source_name": "nih-clinical-trials-phase-2-completed-results",
      "source_url": "https://clinicaltrials.gov/study/NCT05500586?aggFilters=phase%3A2%2Cresults%3Awith%2Cstatus%3Acom",
      "published_date": "2026-10-14"
    },
    {
      "manifest_id": "1791981868392398415",
      "title": "Revefenacin in Acute Respiratory Insufficiency in COPD",
      "source_name": "nih-clinical-trials-phase-2-completed-results",
      "source_url": "https://clinicaltrials.gov/study/NCT04315558?aggFilters=phase%3A2%2Cresults%3Awith%2Cstatus%3Acom",
      "published_date": "2026-10-14"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1791981868392502404",
      "1791981868392680614",
      "1791981868392357036",
      "1791981869274942141",
      "1791981868392495054",
      "1791981868392398415"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Open https://synorb.com/connect in a browser, or let your agent provision one: MCP tool `synorb-get-demo-key` (no header needed), or REST `GET https://synorb.com/connect` with `Accept: application/json`. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; 3 of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1791981868392502404",
      "all": "for id in 1791981868392502404 1791981868392680614 1791981868392357036 1791981869274942141 1791981868392495054 1791981868392398415; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-10-15/trial-readouts/",
    "json": "https://hangingcontext.com/stories/2026-10-15/trial-readouts/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-10-15/trial-readouts/index.md",
    "newsroom": "https://hangingcontext.com/n/health-biotech/",
    "edition": "https://hangingcontext.com/editions/2026-10-15T12/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-10-15/brain-recovery/",
      "headline": "Three new ways to read the brain: coma circuits, dementia pills, and a Parkinson's biomarker",
      "slug": "brain-recovery"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-10-15/cancer-immune-resistance-tools/",
      "headline": "New angles on hard-to-treat cancers: immune readouts, drug pairs, and resistance forecasts",
      "slug": "cancer-immune-resistance-tools"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-10-14/clinical-ai/",
      "headline": "AI moves deeper into the clinic: three deals this week",
      "slug": "clinical-ai"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Run the cited Manifests yourself",
    "text": "Every claim in this paper points to a Manifest id. Get a Synorb Key and read the Manifests behind it. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; 3 of them are starter Beacons.",
    "cta": {
      "label": "Get a key",
      "url": "https://synorb.com/connect"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-10-15/trial-readouts/"
  }
}